ImmunoGen Stock News

ImmunoGen, Inc. (NASDAQ:IMGN) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totalling 17,770,000 shares, a growth of 9.7% from the July

Ralph Nwosu, national chairman of the African Democratic Congress (ADC), says there is a thin line between oppression and revolution. In a statement on Tuesday, Nwosu asked the federal government

Realty Income (NYSE:O) had $60.2 million of unpaid rent as of June 30th. Same Store NOI was negative because of reserves for quick service restaurant rents.

DS Announces Clinical Trial Collaboration with AZ to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated NSCLC

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes

ImmunoGen's hopes rest on Mirvetuximab soravtansine, despite an earlier trial failure. Its market capitalization assumes a high likelihood of success.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.

Nisa Investment Advisors LLC boosted its holdings in shares of Agree Realty Co. (NYSE:ADC) by 122.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Co

Final earnings conference call transcript of Immunogen Inc. - IMGN stock

Teledyne Technologies is featuring a broad range of advanced RF & Microwave products and capabilities this week at the annual International Microw

With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our Chief Financial Officer. Moving to our earlier stage programs, we are plea

ImmunoGen, Inc. (NASDAQ:IMGN) Q2 2020 Results Earnings Conference Call July 31, 2020, 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications and Investor Relatio

ImmunoGen (IMGN) delivered earnings and revenue surprises of 22.22% and 5.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Immunogen (NASDAQ:IMGN) moved higher by 3.0% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 51.72% over the past year to ($0.14), wh